UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
University of California, Davis
Incyte Corporation
Incyte Corporation
NRG Oncology
Incyte Corporation
Stanford University
Novartis
GlaxoSmithKline
AstraZeneca
Pfizer
ADC Therapeutics S.A.
Pfizer
Eli Lilly and Company
Albert Einstein College of Medicine
Vanderbilt University Medical Center
Novartis
Rutgers, The State University of New Jersey
University of Florida
Incyte Corporation
Nektar Therapeutics
Nektar Therapeutics
Incyte Corporation
Merck Sharp & Dohme LLC
Duke University
Pfizer
Incyte Corporation
Bristol-Myers Squibb
Novartis
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
St. Louis University
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
INSYS Therapeutics Inc
Altor BioScience